Journal
PHAGE-THERAPY APPLICATIONS AND RESEARCH
Volume 3, Issue 1, Pages 6-11Publisher
MARY ANN LIEBERT, INC
DOI: 10.1089/phage.2022.29028.nkv
Keywords
antimicrobial resistance; ectolysin; filamentous phages; metagenomics; recombinant phage proteins
Categories
Funding
- LeeKong Chian School of Medicine Strategic Academic Initiative Grant [L0494003]
- A*STAR Grant [C210812044]
- Singapore National Research Foundation (NRF)'s Intra Campus for Research Excellence and Technological Enterprise (CREATE) Seed Collaboration Grant
- Singapore-MIT Alliance for Research and Technology (SMART) Antimicrobial Resistance Interdisciplinary Group - NRF under its CREATE program
- NUS Medpostdoctoral fellowship [NUHSRO/2019/046/PDF/19]
- National University Hospital System Seed Fund [NUHSRO/2019/050/T1/Seed-Mar/03]
- SMART [ING-001014 BIO]
- Singapore Ministry of Health's National Medical Research Council [OFIRG21jun-0038]
- National Health Innovation Centre Singapore Innovation to Develop Grant [NHIC-I2D-2104625]
Ask authors/readers for more resources
This article summarizes the ongoing research on bacteriophages and phage-derived technologies in Singapore and neighboring countries. The symposium discussed topics such as the life cycles and diversity of phages, their roles in biofilms and the human gut microbiome, engineered phage lysins for treating polymicrobial infections in wounds, and the challenges and prospects of clinical phage therapy.
Bacteriophages and phage-derived proteins are a promising class of antibacterial agents that experience a growing worldwide interest. To map ongoing phage research in Singapore and neighboring countries, Lee Kong Chian School of Medicine, Nanyang Technological University Singapore (NTU) and Yong Loo Lin School of Medicine, National University of Singapore (NUS) recently co-organized a virtual symposium on Bacteriophage and Bacteriophage-Derived Technologies, which was attended by more than 80 participants. Topics were discussed relating to phage life cycles, diversity, the roles of phages in biofilms and the human gut microbiome, engineered phage lysins to combat polymicrobial infections in wounds, and the challenges and prospects of clinical phage therapy. This perspective summarizes major points discussed during the symposium and new perceptions that emerged after the panel discussion.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available